Heart attack survivor thanks medics for their kindness
Chris Parsons went to Russells Hall Hospital in Dudley where doctors told him an artery was completed blocked and he needed an urgent angioplasty procedure.
"I was fully conscious during the procedure and the team talked me through each stage," he said.
Now recovered, he is enjoying a healthier lifestyle - including losing 22kg (3.4 stone) - and has thanked the paramedics, nurses, doctors and rehab teams who treated him "with kindness".
Mr Parsons said he had fallen ill in May last year and his wife insisted he sought medical help after struggling to walk.
"Within two minutes of arriving at Russells Hall Hospital's A&E, I was lying on a bed being wired up to an ECG machine," he said.
He was urgently transferred to New Cross Hospital in Wolverhampton where a specialist cardiac team treated him by inserting a stent to open up a completely blocked artery, the hospital trust said.
"From the moment we arrived at A&E to lying in a hospital ward post procedure, only three hours had passed – it was incredible," said Mr Parsons.
He spent three days at New Cross Hospital and continued his recovery with cardiac rehabilitation at Russells Hall, including being given exercise guidance, nutritional advice and emotional support.
"At first, I wasn't sure about counselling, as I felt fine," he said. "But after the first session, I realised how much the heart attack had affected me.
"It helped me process what had happened and gave me the tools to move forward positively."
Nine months later, he continues to exercise regularly and said he felt healthier than he ever had.
"I was made to feel safe and cared for by everyone, from A&E staff to the ambulance crew, nurses, doctors, and rehab teams. They treated me as an individual and with kindness," he said.
"This has helped me get to a position where I am healthier than I have been for years, have a new lease of life, and I'm looking forward to what the future brings."
Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Man who 'died' 27 times thanks hospital
'Appearing in an NHS campaign saved my life'
Royal Wolverhampton NHS Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Baroness Amos to lead NHS maternity and neonatal investigation
The Royal College of Midwives (RCM) has welcomed the selection of Baroness Valerie Amos to lead the investigation into NHS maternity and neonatal care, adding it is 'vital' the review gets under way quickly. Baroness Amos was selected by Health Secretary Wes Streeting after bereaved families expressed a preference for someone with distance from the NHS who is able to bring a fresh pair of eyes to the role, the Department of Health and Social Care (DHSC) said. Mr Streeting has been meeting bereaved and harmed families who have been let down by maternity and neonatal services across the country, including in some of the worst affected trusts, DHSC added. In June, he announced that a national investigation into 'systemic' failures in NHS maternity care had been launched by the Government after families were 'gaslit' in their search for the truth. Baroness Amos is master of University College, Oxford, and was a UK Government minister and a senior official at the United Nations. Mr Streeting said: 'I have been appalled by the many harrowing stories I've heard from mothers and fathers let down by the NHS. 'Families asked for fresh eyes, independence and compassion – and that's why I've appointed Baroness Amos. Valerie has an outstanding record of leadership and driving change, nationally and internationally. She will work closely with families to uncover the truth, confront problems and drive the improvements needed so every woman and baby receives safe, high-quality care. 'Through our Plan for Change, we will rebuild the NHS to ensure no family suffers like this again.' Baroness Amos said: 'I will carry the weight of the loss suffered by families with me throughout this investigation. I hope that we will be able to provide the answers that families are seeking and support the NHS in identifying areas of care requiring urgent reform.' The investigation will look at up to 10 services in the country. It will also review the maternity and neonatal system, bringing together the findings of past reviews into one national set of actions, the DHSC said. It will begin work this summer and produce an initial set of national recommendations by December. The 10 maternity and neonatal units will be decided by Baroness Amos and her team, alongside the terms of reference of the investigation, which are being developed with families who have experiences of maternity and neonatal care, including in Leeds, Sussex and Nottingham, the DHSC added. The investigation is separate from the National Maternity and Neonatal Taskforce, which will be made up of a panel of experts and families, and chaired by Mr Streeting. Gill Walton, chief executive of the RCM, said: 'We are pleased to hear of the appointment of Baroness Amos as chair of the rapid review. She has a reputation for taking a thoughtful and strategic approach and we welcome her fresh insight into maternity and neonatal safety. 'It is absolutely vital, though, that this review gets under way quickly. When he announced it in June, we welcomed Wes Streeting's commitment to publishing the review by Christmas, a promise he repeated at the Progress in Partnership summit on maternity and neonatal safety last month. 'However, we are already halfway through August, with no terms of reference, no sense of the trusts who are likely to be part of the review or no clarity on how the review will be conducted. 'Every woman and family should leave maternity and neonatal services whole, happy and healthy, and every member of maternity staff should start and end their shift knowing they have provided safe, good-quality care. 'At the moment, that simply isn't the case. Previous reviews and countless Care Quality Commission reports have flagged the same the systemic failings that are at the heart of the issues facing maternity and neonatal care issues time and time again: unsafe staffing, poor workplace cultures, and not listening to women. 'In spite of that, there has been no forward movement. Wes Streeting promised to change that. Thousands of midwives and maternity support workers, and the whole of the maternity community, are desperate for him to keep that promise and deliver the change we all want to see.' The RCM has also urged the review to look at examples of good maternity care, as well as where services are not meeting standards of care.
Yahoo
9 hours ago
- Yahoo
Mounjaro weight-loss drug price to almost triple in UK
The price of popular weight-loss jab Mounjaro will nearly triple after the US-owned company equalised costs in markets across the globe. A month's supply of the highest doses of the 'King Kong' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The NHS said the price increase would not affect its commissioning of the medicine for people with obesity and type 2 diabetes. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
CNBC
12 hours ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
